SCHEMBL2774380

SCHEMBL2774380

CN(CCNC(=S)Nc1ccc(F)c(F)c1)CCNc1cc(N2CCCC2)nc(N2CCCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 12/20 0.47
KDM4E B2RXH2 9/20 0.47
HTT P42858 5/20 0.47
LMNA P02545 2/20 0.47
KMT2A Q03164 5/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RAB9A P51151 1/20 0.38
GAA P10253 1/20 0.38
PIK3CD O00329 1/20 0.37
AKT1 P31749 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2775656 0.92 RAD52 (0.46) RAD52KDM4EHTTLMNAKMT2A
SCHEMBL2772283 0.91 KDM4E (0.47) RAD52KDM4EHTTLMNAKMT2A
SCHEMBL2773495 0.89 LMNA (0.48) RAD52KDM4EHTTLMNAKMT2A
SCHEMBL2774140 0.89 RAD52 (0.45) RAD52KDM4EHTTLMNAKMT2A
Hydrochloric Acid SCHEMBL2791558 0.89 LMNA (0.47) RAD52KDM4EHTTLMNAKMT2A
SCHEMBL2774112 0.89 LMNA (0.47) RAD52KDM4EHTTLMNAKMT2A
SCHEMBL2772650 0.88 RAD52 (0.43) RAD52KDM4EHTTLMNAKMT2A
SCHEMBL2772076 0.88 RAD52 (0.47) RAD52KDM4EHTTLMNAKMT2A
SCHEMBL2774074 0.88 LMNA (0.48) RAD52KDM4EHTTLMNAKMT2A
SCHEMBL2774351 0.88 KDM4E (0.47) RAD52KDM4EHTTLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137275-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-06-03 US claimed
EP-2152675-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-02-17 EP claimed
WO-2008152223-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2008-12-18 WO claimed
US-20100137275-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-06-03 US disclosed
EP-2152675-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-02-17 EP disclosed
WO-2008152223-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137275-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE CDC25A, CDC25B, CDC25C RAD52 325/4885KDM4E 2170/4885HTT 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.